First 10 runs free
    Intelligence Feed event · Macro · 2026-10-26

    Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study

    Question

    Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study

    Direct answer

    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-26
    Published
    2026-10-26
    Revision
    1 · 2026-10-28

    Cite as: Market Ontology, “Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study”, revision 1, evidence through 2026-10-26. https://marketontology.com/market-events/2026-10-26/johnson-johnson-reports-77-response-rate-in-phase-1b-2-rybrevant-study-fb4182

    MACRO
    Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention.
    JNJMRK
    Impact
    69
    OCT 26
    SIG
    85%
    JNJMRK
    Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention.
    → A 77% overall response rate in first-line HNSCC creates a clinical foundation for regulatory label expansion, expanding the addressable patient base for J&J's Rybrevant oncology franchise.
    Impact
    Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention.
    Affected
    JNJMRK
    Transmission
    A 77% overall response rate in first-line HNSCC creates a clinical foundation for regulatory label expansion, expanding the addressable patient base for J&J's Rybrevant oncology franchise.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    JNJoncology franchise expansion via Phase 1b/2 frontline head and neck response dataUp1-4wSubcutaneous amivantamab combination achieved a 77% overall response rate in the OrigAMI-4 trial.
    MRKcombination therapy utility for pembrolizumab in expanded oncology indicationsWatch1-4wRegimen combined amivantamab with pembrolizumab and carboplatin.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJUp266.30 2026-10-26PendingPendingPending
    MRKWatch140.61 2026-10-26+0.86%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards